Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins

References

• Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10:2 - 9
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science 2006; 314:777 - 781
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95:13363 - 13383
   PubMed Web of Science ®Google Scholar
• Caughey B, Lansbury PT. Protofibrils, pores, fibrils and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26:267 - 298
   PubMed Web of Science ®Google Scholar
• Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006; 443:774 - 779
   PubMed Web of Science ®Google Scholar
• Stites TE, Mitchell AE, Rucker RB. Physiological importance of quinoenzymes and the O-quinone family of cofactors. J Nutr 2000; 130:719 - 727
   PubMed Web of Science ®Google Scholar
• Killgore J, Smidt C, Duich L, Romero-Chapman N, Tinker D, Reiser K, et al. Nutritional importance of pyrroloquinoline quinone. Science 1989; 245:850 - 852
   PubMed Web of Science ®Google Scholar
• Watanabe A, Tsuchida T, Nishigori H, Urakami T, Hobara N. Davidson VL. Pharmacological Application of PQQ. Principles and Applications os Quinoproteins 1993; 395 - 408
   Google Scholar
• Kasahara T, Kato T. Nutritional biochemistry: A new redox-cofactor vitamin for mammals. Nature 2003; 422:832
   PubMed Web of Science ®Google Scholar
• Zhang Y, Feustel PJ, Kimelberg HK. Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat. Brain Res 2006; 1094:200 - 206
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kim J, Kobayashi N, Han S, Nakamura C, Ikebukuro K, et al. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein. Biochem Biophys Res Commun 2006; 349:1139 - 1144
   PubMed Web of Science ®Google Scholar
• Zameer A, Schulz P, Wang MS, Sierks MR. Single chain Fv antibodies against the 25–35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry 2006; 45:11532 - 11539
   PubMed Web of Science ®Google Scholar
• Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol Dis 2005; 20:74 - 81
   PubMed Web of Science ®Google Scholar
• Liu D, Xu Y, Feng Y, Liu H, Shen X, Chen K, et al. Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide. Biochemistry 2006; 45:10963 - 10972
   PubMed Web of Science ®Google Scholar
• Sabate R, Gallardo M, Estelrich J. An autocatalytic reaction as a model for the kinetics of the aggregation of beta-amyloid. Biopolymers 2003; 71:190 - 195
   PubMed Web of Science ®Google Scholar
• Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, et al. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. Febs J 2005; 272:3661 - 3672
   PubMed Web of Science ®Google Scholar
• Moussa CE, Wersinger C, Tomita Y, Sidhu A. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Biochemistry 2004; 43:5539 - 5550
   PubMed Web of Science ®Google Scholar
• Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem 2004; 279:25497 - 25502
   PubMed Web of Science ®Google Scholar
• Bocharova OV, Breydo L, Parfenov AS, Salnikov VV, Baskakov IV. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). J Mol Biol 2005; 346:645 - 659
   PubMed Web of Science ®Google Scholar
• Kirby L, Birkett CR, Rudyk H, Gilbert IH, Hope J. In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversion. J Gen Virol 2003; 84:1013 - 1020
   PubMed Web of Science ®Google Scholar
• Baskakov IV, Bocharova OV. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features. Biochemistry 2005; 44:2339 - 2348
   PubMedGoogle Scholar
• Kobayashi M, Han S, Nakamura C, Sode K. Nanostructure fabrication based on engineered α-synuclein. Nano Bio Technology 2008; 4:50 - 55
   Google Scholar
• Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006; 67:27 - 37
   PubMed Web of Science ®Google Scholar
• Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem 2004; 279:26846 - 26857
   PubMed Web of Science ®Google Scholar
• Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006; 97:105 - 115
   PubMed Web of Science ®Google Scholar
• Kumar S, Mohanty SK, Udgaonkar JB. Mechanism of formation of amyloid protofibrils of barstar from soluble oligomers: evidence for multiple steps and lateral association coupled to conformational conversion. J Mol Biol 2007; 367:1186 - 1204
   PubMed Web of Science ®Google Scholar
• El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 1998; 440:71 - 75
   PubMed Web of Science ®Google Scholar
• Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr. NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 1996; 35:13709 - 13715
   PubMed Web of Science ®Google Scholar
• Sode K, Ochiai S, Kobayashi N, Usuzaka E. Effect of Reparation of Repeat Sequences in the Human alpha-Synuclein on Fibrillation Ability. Int J Biol Sci 2007; 3:1 - 7
   Web of Science ®Google Scholar
• Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, et al. 3D structure of Alzheimer’s amyloid-beta(1–42) fibrils. Proc Natl Acad Sci USA 2005; 102:17342 - 17347
   PubMed Web of Science ®Google Scholar
• Hornemann S, Korth C, Oesch B, Riek R, Wider G, Wuthrich K, et al. Recombinant full-length murine prion protein, mPrP(23–231): purification and spectroscopic characterization. FEBS Lett 1997; 413:277 - 281
   PubMed Web of Science ®Google Scholar
• Smidt CR, Unkefer CJ, Houck DR, Rucker RB. Intestinal absorption and tissue distribution of [14C]pyrroloquinoline quinone in mice. Proc Soc Exp Biol Med 1991; 197:27 - 31
   PubMed Web of Science ®Google Scholar
• Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G. Recent advances in medicinal chemistry and pharmaceutical technology—strategies for drug delivery to the brain. Curr Top Med Chem 2009; 9:182 - 196
   PubMed Web of Science ®Google Scholar
• Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 2004; 189:380 - 392
   PubMed Web of Science ®Google Scholar
• Lundin A. Use of firefly luciferase in ATP-related assays of biomass, enzymes and metabolites. Methods Enzymol 2000; 305:346 - 370
   PubMed Web of Science ®Google Scholar
• Slater K. Cytotoxicity tests for high-throughput drug discovery. Curr Opin Biotechnol 2001; 12:70 - 74
   PubMed Web of Science ®Google Scholar